<DOC>
	<DOCNO>NCT00979342</DOCNO>
	<brief_summary>The purpose study develop recommended local anesthetic protocol post-treatment pain management regimen , order assure patient comfort office-based treatment MyoSure Hysteroscopic Tissue Removal Device . Subject self-reported pain score ( rat 11 point scale ) compare multiple time interval treatment group .</brief_summary>
	<brief_title>Comparative Sedation Study MyoSure Hysteroscopic Tissue Removal System</brief_title>
	<detailed_description>Forty subject enrol randomize , control study conduct four physician office day surgery setting . Subjects randomize 1:1 local anesthetic group ( Group # 1 Group # 2 ) . Subjects undergo hysteroscopic tissue removal procedure remove intrauterine polyp , type 0 fibroid , type I fibroids . Subsequent procedure , subject randomized 1:1 within local anesthetic group post procedure pain management group ( Group A Group B ) . Subject self-reported pain score ( rat 11 point scale ) compare three time point : Immediately post procedure , prior discharge treatment facility , 48 hour post procedure .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Healthy female age 18 65 Subject must able understand , read sign study specific informed consent form nature study fully explain Subject premenopausal perimenopausal female , either nulliparous parous Subject indicate myomectomy polypectomy benign pathology , base hysteroscopic , ultrasound , saline infuse sonogram assessment within 60 day Subject exhibit intrauterine polyp and/or submucous myoma meet one follow criterion . In case subject multiple intrauterine pathology , classification base follow : All polyps A single Type 0 Type 1 myoma ≤ 3 cm Polyps plus single Type 0 Type 1 myoma ≤ 3 cm Negative pregnancy test within 48 hour prior plan index procedure willing use reliable birth control next 30 day . Reliable birth control define chemical barrier method , include oral contraceptive , injectable contraceptive , combination spermicide condom Known suspect cancer , include breast , endometrial , ovarian Subject Type 2 myoma Contraindication and/or allergy local anesthetic , oral medication specify treatment protocol Subject history chronic narcotic use Previous uterine artery embolization uterine artery occlusion procedure ( Doppler laparoscopic ) Subject blood borne pathogensHIV , hepatitis B , CJD , etc . Subject plan become pregnant within study period Subject IUD time procedure . A subject may enrol study IUD remove prior treatment procedure Subject take anticoagulant antiplatelet medication low dose aspirin Active pelvic inflammatory disease pelvic/vaginal infection Subject know suspect coagulopathy bleed disorder Subject history unmanaged endocrine disease Subject current past , acute chronic psychiatric disorder , opinion Investigator , may preclude proper evaluation followup Subject history autoimmune , inflammatory , connective tissue disease Subject history disease increase risk fluid overload ( i.e . significant cardiac , hepatic , renal dysfunction ) Uncontrolled hypertension last two year Use experimental drug device within 30 day prior screen visit The subject terminal illness may prevent completion followup assessment Any employee relative employee Sponsor company Investigator site employee relative employee work study Subject comorbid condition ( ) , opinion Investigator , could limit subject 's ability participate study impact scientific integrity study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>morcellator</keyword>
	<keyword>hysteroscope</keyword>
	<keyword>myomectomy</keyword>
	<keyword>polypectomy</keyword>
	<keyword>uterine fibroid</keyword>
	<keyword>uterine polyp</keyword>
	<keyword>local anesthetic</keyword>
	<keyword>cervical block</keyword>
	<keyword>pain management</keyword>
</DOC>